Literature DB >> 16127421

Continuous real-time measurement of tumor necrosis factor-alpha converting enzyme activity on live cells.

Montserrat Alvarez-Iglesias1, Gareth Wayne, Kieran P O'Dea, Augustin Amour, Masao Takata.   

Abstract

Tumor necrosis factor-alpha (TNF) converting enzyme (TACE) is responsible for shedding of various membrane proteins including proinflammatory cytokine TNF. In vivo regulation of TACE is poorly understood mainly due to lack of reliable methodology to measure TACE activity in cell-based assays. Here we report a novel enzyme assay that enables continuous real-time measurement of TACE activity on the surface of live cells. Cells were incubated with a new fluorescent resonance energy transfer peptide consisting of a TACE-sensitive TNF sequence and fluorescein-tetramethylrhodamine (FAM-TAMRA), and enzyme activity was monitored by the rate of increase in fluorescent signal due to peptide cleavage. Validation studies using resting as well as stimulated monocytic cells indicated that the assay was sensitive, reproducible and quantitative. Pharmacological studies with various inhibitors indicated that the observed enzyme activity could largely be ascribed to TACE. Thus, the FAM-TAMRA peptide provides a powerful tool for measurement of constitutive and inducible cellular TACE activity. The principles developed may be applied to analyses of enzyme activity of various sheddases on live cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127421     DOI: 10.1038/labinvest.3700340

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  8 in total

1.  Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease.

Authors:  Qiying Sun; Harald Hampel; Kaj Blennow; Simone Lista; Allan Levey; Beisha Tang; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α-converting enzyme.

Authors:  Justin B Schaal; Thorsten Maretzky; Dat Q Tran; Patti A Tran; Prasad Tongaonkar; Carl P Blobel; André J Ouellette; Michael E Selsted
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

3.  Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.

Authors:  Miles A Miller; Layla Barkal; Karen Jeng; Andreas Herrlich; Marcia Moss; Linda G Griffith; Douglas A Lauffenburger
Journal:  Integr Biol (Camb)       Date:  2010-12-23       Impact factor: 2.192

4.  Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor α-converting enzyme (TACE/ADAM-17) activation in primary human monocytes.

Authors:  Alasdair J Scott; Kieran P O'Dea; David O'Callaghan; Lynn Williams; Justina O Dokpesi; Louise Tatton; Jonathan M Handy; Philip J Hogg; Masao Takata
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

5.  Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.

Authors:  Timothy J Bensman; Jordanna G Jayne; Meiling Sun; Elza Kimura; Joshua Meinert; Joshua C Wang; Justin B Schaal; Dat Tran; Adupa P Rao; Omid Akbari; Michael E Selsted; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2.

Authors:  Deepali G Vartak; Bao-Shiang Lee; Richard A Gemeinhart
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

7.  A biosensor for the activity of the "sheddase" TACE (ADAM17) reveals novel and cell type-specific mechanisms of TACE activation.

Authors:  Douglas A Chapnick; Eric Bunker; Xuedong Liu
Journal:  Sci Signal       Date:  2015-02-24       Impact factor: 8.192

8.  Monocyte Tumor Necrosis Factor-α-Converting Enzyme Catalytic Activity and Substrate Shedding in Sepsis and Noninfectious Systemic Inflammation.

Authors:  David J P O'Callaghan; Kieran P O'Dea; Alasdair J Scott; Masao Takata; Anthony C Gordon
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.